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Abstract
Background: Phenoxodiol is a novel isoflavone currently being studied in clinical trials for the treatment of cancer.
This study reports the pharmacokinetics of phenoxodiol in patients with cancer.
Methods: The pharmacokinetics of phenoxodiol was studied following a single intravenous (iv) bolus dose and
during a continuous intravenous infusion. Three men with prostate cancer and 3 women with breast cancer
received IV bolus phenoxodiol (5 mg/kg) and plasma was sampled for free and total phenoxodiol levels. On a
separate occasion 5 of the same patients received a continuous intravenous infusion of phenoxodiol (2 mg/kg/h)
and plasma was again sampled for free and total phenoxodiol levels. Phenoxodiol was measured using gradient
HPLC with ultraviolet detection.
Results: Following bolus injection, free and total phenoxodiol appeared to follow first order pharmacokinetics. The
elimination half-lives for free and total phenoxodiol were 0.67 ± 0.53 h and 3.19 ± 1.93 h, respectively, while the
total plasma clearance rates were 2.48 ± 2.33 L/h and 0.15 ± 0.08 L/h, respectively. The respective apparent
volumes of distribution were 1.55 ± 0.69 L/kg and 0.64 ± 0.51 L/kg. During continuous intravenous infusion, free
phenoxodiol accumulated rapidly to reach a mean concentration at steady state of 0.79 ± 0.14 μg/ml after 0.87 ±
0.18 h. The apparent accumulation half-life of free phenoxodiol was 0.17 ± 0.04 h while the plasma clearance
during continuous infusion was 1.29 ± 0.23 L/h.
Conclusions: Phenoxodiol has a short plasma half-life, particularly in the free form, leading to a rapid attainment
of steady state levels during continuous intravenous infusion.
Trial registration: Australian New Zealand Clinical Trials Registry (ANZCTR): +ACTRN12610000334000
Background
Phenoxodiol (PXD, NV-06) is an isoflavone derivative
that has been demonstrated in vitro and in vivo to pos-
sess anti-cancer activity [1-9]. Phenoxodiol is a synthetic
analogue of genistein with unknown mechanism of
action. It appears to have pleiotropic actions such as
inhibition of tyrosine kinases, inhibition of topoisome-
rase II in a dose-dependent manner and inhibition of
the X-linked inhibitor of apoptosis [2,10-12] but the
predominant mode of action remains to be elucidated.
A series of intriguing observations were made by Morre
et al. [13-16], who showed that phenoxodiol acts by
inhibiting ENOX2 (tNOX), a tumour-associated cell sur-
face ubiquitinol (NADH) oxidase, which functions as an
alternative pathway for plasma membrane electron
transport. Further, phenoxodiol has the ability to modu-
late chemoresistance and promote apoptosis of ovarian
cancer cells [2,17,18]. These anti-cancer properties have
generated much interest in phenoxodiol as a potential
cancer treatment.
Phase I studies of phenoxodiol have been previously
published [19,20], and the molecule was being studied
in a Phase III clinical trial in the treatment of ovarian
cancer until recently, when the study was halted prior to
full accrual. At the time this study was performed in
2000, we had no information regarding the behaviour of
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was a pharmacokinetic study to investigate both bolus
and continuous intravenous administration. This paper
presents data derived from that first-in-human, pharma-
cokinetic study, and our aim at the time was to deter-
mine the pharmacokinetic parameters of phenoxodiol in
order to inform us further about the design of Phase I
and other studies.
Methods
A single centre, open-label pharmacokinetic study invol-
ving six patients with metastatic cancer was performed
between April 2000 and November 2000. Each patient
was recruited in a serial manner and given a single
intravenous (iv) injection of phenoxodiol over a five
minute period at a dose of 5 mg/kg initially. At least
6 weeks after their individual intravenous bolus adminis-
tration, each patient was then given a continuous infu-
sion of phenoxodiol at a rate of 2 mg/kg per hour for a
duration of up to ten times the average half life deter-
mined from the data obtained after intravenous bolus
dosing. No continuous intravenous infusion occurred
until all the pharmacokinetic data from intravenous
bolus dosing was available. The intravenous bolus dose
of phenoxodiol was selected as 10% of bolus intravenous
doses achievable in mice up to 50 mg/kg that had
demonstrated no discernible toxicity, including histo-
pathological evaluation (data on file, Novogen Pty Ltd).
Subjects
Six patients were studied in total. The inclusion criteria
were: male or female volunteers with metastatic disease
from any solid tumour, age 18 to 70 years, normal hae-
matological parameters, and a prognosis of at least three
months. Exclusion criteria were: leukemia or lymphoma,
allergy to soy products, vegetarian diet or use of soy
product more than three times a week, the use of sex
steroids in the previous two months, antibiotic therapy
within one month prior to the study period or at any
time during the study, smoking of greater than 10 cigar-
ettes/day, and the known presence of central nervous
system metastases. Active infection or other co-morbid
disease that in the opinion of the investigator would
have precluded the patient from participating in the
study was also an exclusion criterion. Patients also had
to have relatively stable or slow growing tumours and
not commence new anti-cancer therapies while on
study. The study was approved by the Ethics Committee
of St George Hospital (00/13 Howes), and patients had
written, fully informed consent.
Study protocol
Screening procedures included a medical history, full
physical examination, haematology and biochemistry.
Volunteers were then assessed for compliance with the
inclusion and exclusion criteria. All patients were
instructed to maintain a diet low in isoflavones for one
week prior to and for the duration of the study, and to
arrive at the hospital on the treatment day at approxi-
mately 0800 having fasted and abstained from caffeine
and alcohol for 24 hours (h). An initial blood sample of
40 ml was drawn from an antecubital vein-indwelling
catheter at baseline prior to study medication adminis-
tration. Blood draws were planned at 0.0 (baseline, prior
to infusion), 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 5.0, 6.0, 7.0,
8.0, 10.0 and 12.0 h after the administration of phenoxo-
d i o l .As t a n d a r d ,l i g h t ,l o wf a tm e a lw a sp r o v i d e d
4 hours after the administration of study medication.
After observation for 12 hours, the indwelling intrave-
nous catheter was removed and the patient advised not
to consume alcohol over the ensuing 24-hour period.
At least 6 weeks after their intravenous bolus dose,
patients were recalled individually for their continuous
intravenous infusion. The same diet and preparation
was required prior to dosing. Fifteen ml of blood was
collected at baseline and at 10 and 20 minutes following
the start of infusion of phenoxodiol, then at 20 minute
intervals up to five hours after the commencement of
the infusion. A standard, light, low fat meal was pro-
vided 4 hours after the administration of study medica-
tion. Both indwelling venous catheters were removed six
hours after commencement of the infusion and the
patient was then allowed to leave the hospital following
a period of observation.
Safety assessments
Laboratory Safety Testing
The following tests were performed at baseline, 24 h,
and 48 h after intravenous bolus dosing, and at baseline,
6h ,57d a y sa n d1 21 4d a y sa f t e rt h es t a r to fc o n t i n u -
ous intravenous infusion: full blood count (FBC) includ-
ing hemoglobin, red cell count, white cell count and
differential, platelets, as well as serum biochemistry
including total protein, albumin, aspartate aminotrans-
ferase (AST), alanine aminotransferase (ALT), gamma-
glutamyl transferase (GGT), alkaline phosphatase
(ALKP) and urea and electrolytes.
Vital Signs and Other Safety Measurements
The patient’s weight, height and blood pressure and
heart rate were measured at baseline; blood pressure
and heart rate were monitored throughout the study.
Study medication administration
Phenoxodiol was manufactured by Novogen Labo-
ratories, 140 Wicks Road, North Ryde NSW 2119,
Australia, and was prepared as an intravenous injection
of 100 mg in a 10 ml vial. Samples of the batches of
vials used were tested for sterility and for the presence
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noxodiol was diluted to a total volume of 50 ml in nor-
mal saline. The solution was infused over a five minute
period using an infusion pump. For continuous intrave-
nous infusion, phenoxodiol was diluted to 500 ml in
normal saline and infused using a pump at a constant
rate of 100 ml per hour.
Assay of phenoxodiol levels
Total phenoxodiol levels were measured in a 300 μLa l i -
quot of plasma or urine which was mixed with 15 μL
glucuronidase and incubated for 24 h at 24°C prior to
extraction. Free phenoxodiol levels were measured in a
300 μL aliquot of plasma or urine which was extracted
without prior incubation with glucuronidase. After adding
10 μLo f2 ,4 ,4 ’- trihydroxydeoxy-benzoin (0.22 mg/mL)
as an internal standard, the sample was extracted using an
ethylacetate : hexane (6:4) solution 500 μL. The sample-
solvent mixture was centrifuged at 1200 g for 15 min and
supernatant was collected and dried under vacuum. The
extract was reconstituted in 100 μL 50% isopropanol in
water. 5 uL of the extracted sample was injected into the
HPLC system. Standards of phenoxodiol were prepared in
blank plasma or urine.
HPLC separation was carried out using an Alltech All-
tima C18, 5 μm, 250 mm × 2.1 mm column in a 40°C
oven. The gradient elution was performed at a flow rate
of 0.2 mL/min from mobile phase A (25% acetonitrile,
74.95% water, 0.05% trifluoroacetic acid) to mobile
phase B (99.95% acetonitrile, 0.05% trifluoroacetic acid).
The fraction of mobile phase A to mobile phase B at 0,
4.5, 9, 11, 12 and 14 minutes were 75:25, 40:60, 30:70,
0:100, 0:100 and 75:25 respectively. With 6 minutes post
run, the total run time was 20 minutes. Phenoxodiol
and the internal standard (benzoin) were detected by
ultraviolet diode array detector at wavelength 335 nm.
The approximate retention time for benzoin and phe-
noxodiol were 6.7 minutes and 8.4 minutes, respectively.
The calibration curve for the assay was linear in the
range of 0.25 ug/mL to 10 ug/mL with a correlation
coefficient (R
2)>0.994. The lower limit of quantitation
(LOQ) for phenoxodiol was 0.25 ug/mL. Samples with
high concentrations were diluted with the same blank
matrix before being analysed. As phenoxodiol has very
good absorption at 335 nm and blank biological matrix
has much less UV absorption at this wavelength, co-
elution did not cause any problems with regards to
interpretation. Some samples were analysed using both
HPLC-UV and LC-MS-MS methods and the results
were similar, thus validating our study data.
Pharmacokinetic analysis
The concentration at steady state (Css)a n dt h et i m et o
reach steady state were taken as the actual values when
the measured plasma phenoxodiol concentration
appeared to reach a maximum. The terminal elimination
rate constant (Kel) was estimated using linear regression
analysis using the final plasma sampling times over
which the log of the plasma concentration versus time
curve appeared to be straight. At least four plasma con-
centration time points were used for each estimation.
The elimination half life (T1/2) was calculated as 0.693/
Kel. The area under the plasma concentration versus
time curve (AUC) was calculated using the trapezoid
rule with the terminal phase (last measured plasma con-
centration time point to infinity) calculated as the final
plasma concentration divided by Kel. The apparent
volume of distribution (Vd) following acute administra-
tion in Part 1 of the study was calculated by extrapolat-
ing the log plasma concentration versus time line back
to zero time to estimate the theoretical plasma concen-
tration at zero time (C0) and dividing C0 by the dose.
Clearance following acute administration was calculated
as Vd multiplied by Kel.
Accumulation half-lives during continuous intrave-
nous infusions of phenoxodiol were calculated as the
time to achieve steady state plasma concentrations
divided by 5. Clearance (Cl) was calculated as the infu-
sion rate of phenoxodiol divided by the plasma concen-
tration at steady state (Css). Pharmacokinetic analysis
was performed with the assistance of the Excel software
plug-in program pkf (Joel I. Usansky, Ph.D., Atul Desai,
M.S. and Diane Tang-Liu, Ph.D., Department of Phar-
macokinetics and Drug Metabolism, Allergan, Irvine,
CA 92606, U.S.A). The results are expressed as the
mean values for the subject group along with standard
deviations (SD) and ranges.
Results
Patients
Six patients (3 males, 3 females) were given intravenous
bolus doses of phenoxodiol, but only five went on to
receive continuous intravenous infusion. The patient
who missed out on continuous intravenous infusion had
developed progression of her disease and was advised by
her oncologist to proceed with other treatments; there
was no evidence that the single administration of phe-
noxodiol had contributed to her disease progression.
Continuous intravenous infusion occurred an average of
56 ± 21 days (range 41-98 days) following intravenous
bolus dosing of phenoxodiol. The mean age of the
patients was 61.2 ± 9.4 years, their mean weight was
75.3 ± 8.48 kg and their mean height was 169.2 ± 10.0
cm. One patient smoked (5 cigarettes per day), 3
patients consumed between 10 and 30 g of alcohol per
day and 3 patients did not regularly consume alcohol.
The 3 female patients had metastatic breast cancer
and had a diagnosis of the primary malignancy 15, 7
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static prostate cancer and two of these patients had a
diagnosis of the primary malignancy 6 years prior to the
study. The date of diagnosis of the primary malignancy
for the remaining male was unknown. Patients predomi-
nately had bone metastases, although one male had
known hepatic metastases. One male patient also had a
history of laryngectomy for malignant disease. One
patient had bilateral leg oedema and hepatic enlarge-
ment on physical examination. Clinical examination
findings in the remaining patients were unremarkable.
One patient had mild thrombocytopenia at baseline,
but haematology parameters were otherwise within nor-
mal limits for the remaining patients. Three patients
had abnormal liver function tests at baseline; two had
serum ALKP levels 3-5 times the upper limit of normal
(ULN), one had GGT levels 9 × ULN, and one had a
GGT level 1-2 × ULN. All six patients had normal renal
function and normal serum electrolyte levels.
Pharmacokinetics
Summaries of the pharmacokinetic data for free and total
phenoxodiol following the single intravenous bolus dose
are presented in Tables 1 and 2. Plasma concentration ver-
sus time plots for free and total phenoxodiol for these
patients are presented in Figures 1 and 2. Linear regression
of log plasma concentration versus time plots indicate that
phenoxodiol appeared to follow first order kinetics in all
patients (that is, a single phase of elimination from
plasma). This was the case for both free and total phenox-
odiol. Total phenoxodiol had a longer plasma elimination
half-life than free phenoxodiol, but both were relatively
short (mean values 3.19 ± 1.93 h and 0.67 ± 0.53 h, respec-
tively). These short half-lives were associated with rela-
tively high mean total plasma clearance rates of 2.48 ±
2.33 L/h and 0.15 ± 0.08 L/h respectively. The apparent
volumes of distribution (Vd)a ts t e a d ys t a t ef o rf r e ea n d
total phenoxodiol were relatively low (1.55 ± 0.69 L/kg
and 0.64 ± 0.51 L/kg, for free and total phenoxodiol,
respectively) and total phenoxodiol had a lower volume of
distribution than free phenoxodiol. The area under the
plasma concentration versus time curves for (AUC) total
phenoxodiol following the bolus intravenous dose in Part
1 of the study was approximately 15 times greater than for
free phenoxodiol.
Summaries of the pharmacokinetic data for free and
total phenoxodiol from the 5 patients who had continu-
ous intravenous dosing are presented in Tables 3 and 4.
Plasma concentration versus time plots for free and
total phenoxodiol for these patients are presented
in Figures 3 and 4. Plasma levels of free phenoxodiol
accumulated fairly rapidly with a mean accumulation
half-life of 0.17 ± 0.04 hours. Plasma levels of total phe-
noxodiol accumulated at a relatively slower rate with a
mean accumulation half life of 2.78 ± 0.96 hours. Steady
state plasma levels of total phenoxodiol were more vari-
able than steady state plasma levels of free phenoxodiol
(Figures 3 and 4). The mean clearance rate for total
phenoxodiol (0.06 ± 0.01 L/h) was lower than that of
free phenoxodiol (1.29 ± 0.23 L/h). In two of the
patients (patient 1 and patient 2) the infusion did not
appear to be continued long enough for total phenoxo-
diol to reach steady state plasma levels. As a result,
though the final plasma concentration time point in
these patients was used to estimate Css, accumulation
half-life and clearance, the calculated values are likely to
be underestimated.
Urine excretion of free and total phenoxodiol, respec-
tively, ranged from 0.5 mg - 5.2 mg and 13 - 42 mg
after intravenous bolus dosing (data not shown). Urine
excretion of phenoxodiol after continuous intravenous
infusion was not measured.
Conjugation
The degree of phenoxodiol conjugation is estimated at
91%, based on calculation of the proportion of free
Table 1 Pharmacokinetic parameters for free phenoxodiol following a single bolus dose of 5 mg/kg infused
intravenously over 5 minutes
Patient Kel T1/2 (h) AUC0-t (μg.h/ml) AUC0-inf (μg.h/ml) Cl (L/h) Vd (L/kg)
1 1.25 0.55 1.49 1.55 (4.1%)* 1.50 1.20
2 2.42 0.28 0.40 0.40 (1.2%) 7.01 2.90
3 1.59 0.43 1.04 1.05 (13.2%) 2.22 1.40
4 1.24 0.56 1.65 1.66 (10.3) 1.24 1.00
5 0.39 1.74 2.59 2.59 (11.3) 0.46 1.17
6 1.54 0.45 1.21 1.22 (11.8%) 2.46 1.60
Mean ± SD 1.41 ± 0.66 0.67 ± 0.53 1.40 ± 0.73 1.41 ± 0.73 (8.7%) 2.48 ± 2.33 1.55 ± 0.69
Kel is the elimination rate constant. T1/2 is the terminal half life. AUC0-t is the area under the plasma concentration versus time curve measured to the last
plasma sample. AUC0-inf is the area under the plasma concentration versus time curve extrapolated to infinity. Cl is the plasma clearance rate. Vd is the apparent
volume of distribution. *The figures in parentheses are the estimated free phenoxodiol proportion for each patient, based on the calculation free AUC0-inf x100/
total AUC0-inf.
Howes et al. BMC Clinical Pharmacology 2011, 11:1
http://www.biomedcentral.com/1472-6904/11/1
Page 4 of 8phenoxodiol AUC : total phenoxodiol AUC (mean 8.7%)
from bolus administration. For each individual subject,
estimated proportion of free phenoxodiol from the
bolus data correlates very well with total phenoxodiol
clearance as measured during continuous infusion (data
not shown).
Adverse events
In total, five adverse events were reported from 2
patients; no other patients had adverse events. One
patient experienced 3 serious adverse events: hepatic
metastasis, leg oedema and thrombocytopenia; all of
these had been present prior to the study but had
increased in severity during the study. They were con-
sidered to be due to disease progression and unrelated
to the study medication. This patient died 7 days after
continuous intravenous infusion of phenoxodiol. His
death was considered to be due to rapid progression of
malignant disease and unrelated to the study medica-
tion. The second patient experienced two non-serious
adverse events: groin pain and nausea. The groin pain
occurred the day following the single bolus dose of phe-
noxodiol and was considered not to be related to the
study medication. The episode of nausea occurred fol-
lowing the continuous intravenous infusion of phenoxo-
diol, was mild in intensity, and was considered to be
possibly related to study medication. The episode of
nausea did not require intervention and resolved
spontaneously.
Discussion
This first - in - human study investigated the pharmaco-
kinetics of phenoxodiol, a novel isoflavone, given as a
single intravenous bolus injection and as a single
Table 2 Pharmacokinetic parameters for total phenoxodiol following a single bolus dose of 5 mg/kg infused
intravenously over 5 minutes
Patient Kel T1/2 (h) AUC0-t (μg.h/ml) AUC0-inf (μg.h/ml) Cl (L/h) Vd (L/kg)
1 0.21 3.33 27.10 37.76 0.06 0.31
2 0.25 2.71 33.47 34.64 0.05 0.21
3 0.37 1.85 7.45 7.93 0.29 0.80
4 0.29 2.32 14.19 16.13 0.15 0.50
5 0.35 1.98 21.12 22.83 0.15 0.45
6 0.09 6.98 10.37 10.37 0.16 1.60
Mean ± SD 0.26 ± 0.10 3.19 ± 1.93 18.93 ± 10.11 21.61 ± 12.45 0.15 ± 0.08 0.64 ± 0.51
Abbreviations are the same as for Table 1.
Figure 1 Free phenoxodiol levels following bolus intravenous administration of 5 mg/kg of phenoxodiol over 5 minutes.
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patients. We showed that mean plasma levels of free
phenoxodiol declined rapidly from an initial value of
around 3 μg/ml with an apparent half-life of 0.67 h. The
clearance of free phenoxodiol was relatively high (2.48
L/h) and the volume of distribution was 1.55 L/kg, indi-
cating distribution of the drug into a body compartment
approximately 2.3 times the extracellular fluid volume.
Plasma levels of total phenoxodiol declined from an
initial value of approximately 8 μg/ml with an apparent
half-life of 3.19 h. Similar to free phenoxodiol, the log-
plasma concentration plot for each patient appeared lin-
ear (data not presented) suggesting first order
pharmacokinetics. The clearance of total phenoxodiol
(0.15 L/h) was considerably lower than for free phenox-
odiol. In contrast, the volume of distribution of total
phenoxodiol (0.64 L/kg) was smaller than for free phe-
noxodiol. Plasma concentrations of total phenoxodiol
were more variable than for free phenoxodiol. The ratio
of AUC free phenoxodiol : AUC total phenoxodiol was
0.087, indicating that >90% of the drug following an
intravenous bolus was present in the conjugated form.
Furthermore, the initial plasma concentrations of total
phenoxodiol were approximately 2.7 times the initial
plasma concentrations of free phenoxodiol. These
Figure 2 Total phenoxodiol levels following the bolus intravenous administration of 5 mg/kg of phenoxodiol over 5 minutes.
Table 3 Pharmacokinetic parameters for free
phenoxodiol infused at a dose of 2 mg/kg/h
Css (μg/ml) Time to ss (h) Acc T1/2 (h) Cl (L/h)
1 0.92 0.67 0.13 1.08
2 0.65 1.00 0.20 1.53
4 0.77 1.00 0.20 1.28
5 0.66 1.00 0.20 1.51
6 0.96 0.67 0.13 1.03
Mean ± SD 0.79 ± 0.14 0.87 ± 0.18 0.17 ± 0.04 1.29 ± 0.23
Css is the plasma concentration at steady state. Time to steady state is the
time taken to reach Css. Acc T1/2 is the accumulation half-life. Cl is the
plasma clearance rate.
Table 4 Pharmacokinetic parameters for total










1* 14.74 3.66 0.73 0.06
2* 32.31 4.00 0.80 0.03
4 13.33 2.00 0.40 0.07
5 14.80 2.00 0.40 0.07
6 12.04 2.33 0.47 0.08
Mean ± SD 17.45 ±
8.38
2.78 ± 0.96 0.56 ± 0.19 0.06 ±
0.01
Abbreviations are the same as for table 3. * In patients 1 and 2 the infusion
was not continued long enough to reach steady state and the values
calculated are therefore underestimates of the valid results.
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phenoxodiol in the liver and a slower clearance of con-
jugated than free phenoxodiol. Urine excretion of phe-
noxodiol was difficult to interpret because of missing
data points from incomplete urine collections. Neverthe-
less, it appears that 8 hours was not sufficiently long for
the complete collection of all phenoxodiol excreted by
renal mechanisms.
Following continuous intravenous infusion, plasma
concentrations of free plasma phenoxodiol rose rapidly
with an apparent accumulation half-life of 0.17 h.
Although this appeared to be a little shorter than the
half-life estimated following the single intravenous bolus
dose in Part 1 of the study, the results were also more
variable in Part 1 of the study. The plasma clearance
calculated during the continuous infusion (1.29 L/h)
appeared a little lower than following intravenous
bolus dosing, but the results were consistent with each
other. Further, the degree of individual phenoxodiol
conjugation estimated from the bolus part of the study
correlated well with clearance measured in the continu-
ous infusion part of the study. The mean plasma con-
centrations of free phenoxodiol at steady state were
approximately 0.79 μg/ml, which is broadly in the range
that has been demonstrated to have anti-cancer effects
in in vitro studies.
Since this study was performed however, two publica-
tions regarding phenoxodiol pharmacokinetics have
appeared in print [19,20]. In a 7 day infusion study of
phenoxodiol, steady state levels were reached in 14 of
19 patients [20]. Phenoxodiol doses were escalated in
patient cohorts, ranging from 0.65 mg/kg/24 h to
27 mg/kg/24 h. Overall mean accumulation half-life of
conjugated phenoxodiol was 10.63 h, and time to Css
was 53.14 h with a clearance rate of 0.0260 L/Kg/h [20].
At the closest dose cohort to the present study (2.2 mg/
kg/24 h), mean Css was 4.8 μg/ml. In a study of weekly
intravenous bolus phenoxodiol [19], clearance of total
phenoxodiol was found to be higher (around 82 ml/
min) and half-life longer (around 300 mins) than in this
study. Interestingly, clearance of phenoxodiol was simi-
lar in these two studies to our present study, but half-
life was significantly longer. It is important to note that
comparison across studies is problematic, since one
study reported parameters concerning conjugated phe-
noxodiol only [20], whereas this study and the weekly
bolus study measured free and total phenoxodiol.
Further, the significance of conjugation is unclear,
though we hypothesize that free phenoxodiol is the
most biologically active, and therefore the most impor-
tant moiety. Other reasons for the discrepancy between
pharmacokinetic parameters in the different studies
include different methods for assay (HPLC in this study,
LC-MS in the other two), and the use of a different
(cyclodextrin) carrier for phenoxodiol in the Phase I stu-
dies. Other than the different preparation, other possible
explanations include the tight control of diet, caffeine
and smoking in this study, whereas conditions were not
stated in the Phase I studies.
The limitations of our study are that only a small
number of patients with cancer were studied due to the
fact that it was a first -in-human Phase 1 study of Phe-
noxodiol. In addition, we examined only a limited dose
range of phenoxodiol, so we cannot comment on
whether the pharmacokinetics of phenoxodiol are truly
linear on the basis of this study. Furthermore, the effects
of age and of renal or hepatic dysfunction on phenoxo-
diol pharmacokinetics are not known. Further studies
are required to address these issues.
Conclusions
In conclusion, the results of our study indicate that
phenoxodiol has a very short half-life when given
Figure 3 Mean plasma concentrations of free phenoxodiol
during continuous intravenous infusion of phenoxodiol at 2
mg/kg/h.
Figure 4 Mean plasma concentrations of total phenoxodiol
during continuous intravenous infusion of phenoxodiol at 2
mg/kg/h.
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pharmacokinetic variance within (our study) and
between individuals [19,20] is very wide, it would
appear that administration of phenoxodiol by continu-
ous infusion or by chronic oral administration may be
the optimal modes of administration if it considered
that constant plasma levels are desirable for anti-can-
cer therapy.
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